These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8858455)

  • 1. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients.
    Ballestero S; Fernández-Rodríguez A; Villaverde R; Escobar H; Pérez-Díaz JC; Baquero F
    J Antimicrob Chemother; 1996 Jul; 38(1):39-45. PubMed ID: 8858455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM; Yang YJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France.
    Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM
    Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.
    Dib C; Trias J; Jarlier V
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):979-86. PubMed ID: 8654449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
    Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
    Bretonnière C; Maitte A; Caillon J; Potel G; Boutoille D; Jacqueline C; Guitton C
    J Antibiot (Tokyo); 2016 Nov; 69(11):806-810. PubMed ID: 27025352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
    Kim CH; Kang HY; Kim BR; Jeon H; Lee YC; Lee SH; Lee JC
    J Microbiol; 2016 Jan; 54(1):44-49. PubMed ID: 26727901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Christenson JC; Korgenski EK; Daly JA
    J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase.
    Minami S; Akama M; Araki H; Watanabe Y; Narita H; Iyobe S; Mitsuhashi S
    J Antimicrob Chemother; 1996 Mar; 37(3):433-44. PubMed ID: 9182100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.
    Ocampo-Sosa AA; Cabot G; Rodríguez C; Roman E; Tubau F; Macia MD; Moya B; Zamorano L; Suárez C; Peña C; Domínguez MA; Moncalián G; Oliver A; Martínez-Martínez L;
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1703-13. PubMed ID: 22290967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
    Pournaras S; Ikonomidis A; Markogiannakis A; Spanakis N; Maniatis AN; Tsakris A
    J Med Microbiol; 2007 Jan; 56(Pt 1):66-70. PubMed ID: 17172519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S; Ghozzi R; Burghoffer B; Arlet G; Redjeb S
    Pathol Biol (Paris); 2009; 57(7-8):530-5. PubMed ID: 18977099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.